ClinicalTrials.gg
CompletedNCT05425446Updated Jan 31, 2025

Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients

A Phase 1 interventional study of DONQ52 and Placebo in Celiac Disease, sponsored by Chugai Pharmaceutical. Completed at 21 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-01-31.

Sponsored by Chugai Pharmaceutical (part of Hoffmann-La Roche) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2024, 2 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 103 studies in Celiac Disease with a site in United States — 16 open to participants now, 20 under way, none of them phase 3. Celiac Disease · United States.

Enrollment
31st of 68
56 · median 46
Started
2022
with 7 others
Phase 1
16 of 103
1 open now
Registered
83rd of 103
by date
Lead sponsor
3 of 103
Chugai Pharmaceutical

Among the 103 studies in Celiac Disease with a site in United States, this one is the 31st largest by enrollment of the 68 interventional ones that give a count, is one of 8 that started in 2022, is one of 16 in phase 1, and was the 83rd registered.

Celiac Disease

352 studies on the registry are indexed under Celiac Disease; 77 are open to participants now.

Browse Celiac Disease studies →

Open to participants now

16 of the 103 studies in Celiac Disease with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 48 Celiac Disease studies recruiting now, 24 (50%) set no upper age limit and 19 (40%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Celiac Disease with a site in United States, or all of them as a file.
02

Study summary

This study is to characterize the safety and tolerability of an investigational drug called DONQ52 and consists of a single ascending dose part (Part A) and a multiple ascending dose part (Part B) in well-controlled celiac disease patients.

03

Conditions studied

  • Celiac Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of medically diagnosed celiac disease based on and positive celiac serology.
  • Be on a GFD for at least 12 months
  • HLA-DQ2.5 genotype
  • Experienced at most mild symptoms of celiac disease

Exclusion criteria

Exclusion Criteria:

  • celiac disease
  • Positive for any of the 3 serology (-Tissue transglutaminase-2,- Deamidated gliadin peptide-IgA, and deamidated gliadin peptide-IgG)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    SAD Cohort 1

    All randomized patients will receive one dose of either DONQ52 Dose A or placebo

    Drug: DONQ52 · Drug: Placebo

  • Experimental
    SAD Cohort 2

    All randomized patients will receive one dose of either DONQ52 Dose B or placebo

    Drug: DONQ52 · Drug: Placebo

  • Experimental
    SAD Cohort 3

    All randomized patients will receive one dose of either DONQ52 Dose C or placebo

    Drug: DONQ52 · Drug: Placebo

  • Experimental
    SAD Cohort 4

    All randomized patients will receive one dose of either DONQ52 Dose D or placebo

    Drug: DONQ52 · Drug: Placebo

  • Experimental
    MAD Cohort 1

    All randomized patients will receive multiple dose of either DONQ52 Dose E or placebo

    Drug: DONQ52 · Drug: Placebo

  • Experimental
    MAD Cohort 2

    All randomized patients will receive multiple dose of either DONQ52 Dose F or placebo

    Drug: DONQ52 · Drug: Placebo

  • Experimental
    MAD Cohort 3

    All randomized patients will receive multiple dose of either DONQ52 Dose G or placebo

    Drug: DONQ52 · Drug: Placebo

Interventions

  • DrugDONQ52

    Subcutaneous (SC) injection

  • DrugPlacebo

    Subcutaneous (SC) injection

06

What researchers measure

Primary outcomes

  1. Incidence and severity of treatment-emergent adverse events (TEAEs) as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 or higher

    Incidence and severity of TEAEs and its relationship to the study drugs

    Time frame: Up to 246 days

  2. Safety as assessed by Vital signs (blood pressure, body temperature, pulse rate, respiratory rate, percutaneous oxygen saturation)

    Abnormality in vital signs

    Time frame: Up to 246 days

  3. Safety as assessed by Electrocardiograms (ECGs; QT interval, heart rate)

    Abnormality in Electrocardiograms (ECGs)

    Time frame: Up to 246 days

  4. Safety as assessed by Laboratory tests (hematology, blood chemistry, coagulation and urinalysis)

    Incidence of laboratory abnormalities, based on clinical laboratory tests

    Time frame: Up to 246 days

Secondary outcomes

  1. Pharmacokinetics; Serum DONQ52 concentration

    Serum DONQ52 concentrations over time

    Time frame: Up to 246 days

  2. Pharmacokinetics; Maximum serum concentration [Cmax]

    Cmax of DONQ52

    Time frame: Up to 246 days

  3. Pharmacokinetics; Time to maximum serum concentration [Tmax]

    Tmax of DONQ52

    Time frame: Up to 246 days

  4. Pharmacokinetics; Area under the serum concentration time curve [AUC]

    AUC of DONQ52

    Time frame: Up to 246 days

  5. Pharmacokinetics; Half life [T1/2]

    T1/2 of DONQ52

    Time frame: Up to 246 days

  6. Immunogenicity

    Prevalence and incidence of anti-drug antibodies (ADAs) to DONQ52

    Time frame: Up to 246 days

07

Study locations

21 sites
  • Pinnacle Research Group
    Anniston, Alabama 36207, United States
  • Mountain View Clinical Research
    Denver, Colorado 80209, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
  • Clinical Site Partners
    Leesburg, Florida 34748, United States
  • Clinical Site Partners - Orlando
    Winter Park, Florida 32789, United States
  • Velocity Clinical Research - Boise
    Meridian, Idaho 83642, United States
  • Tandem Clinical Research
    Marrero, Louisiana 70072, United States
  • Mayo Clinic - Rochester
    Rochester, Minnesota 55095, United States
  • Long Island Gastrointestinal Research Group
    Great Neck, New York 11023, United States
  • Columbia University Medical Center
    New York, New York 10019, United States
  • Lucas Research - Diabetes & Endocrinology Consultants, PC
    Morehead City, North Carolina 28557, United States
  • North Carolina Clinical Research
    Raleigh, North Carolina 27607, United States
  • Aventiv Research, Inc.
    Columbus, Ohio 43213, United States
  • Digestive Specialists Inc
    Dayton, Ohio 45414, United States
  • Velocity Clinical Research, Anderson
    Anderson, South Carolina 29621, United States
  • Alliance for Multispecialty Research
    Knoxville, Tennessee 37920, United States
  • Digestive Research of Central Texas
    Waco, Texas 76712, United States
  • Care Access Research
    Ogden, Utah 84403, United States
  • Campbelltown Hospital
    Campbelltown, New South Wales 2560, Australia
  • University of Sunshine Coast Clinical Trials Centre - Morayfield
    Morayfield, Queensland 4506, Australia
  • Linear Clinical Research
    Nedlands, Western Australia 6009, Australia
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform. For further details on Chugai's Data Sharing Policy and how to request access to related clinical study documents, see here (www.chugai-pharm.co.jp/english/profile/rd/ctds_request.html).

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Aug 2024, 22 months.

Of 14 phase 1 interventional studies under Celiac Disease, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 22 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2022
First posted
Jun 21, 2022
StartActual
Sep 19, 2022
Primary completionActual
Aug 9, 2024
CompletionActual
Jan 17, 2025
Last update
Jan 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05425446
Responsible party
Sponsor
First posted
Jun 21, 2022
Start date
Sep 19, 2022
Primary completion
Aug 9, 2024
Completion
Jan 17, 2025
Last update
Jan 31, 2025

Study contacts

Sponsor Chugai Pharmaceutical Co. Ltd
study director · clinical-trials@chugai-pharm.co.jp

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion